Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis

PURPOSE: Previous report from the ASCEND-8 trial showed consistent efficacy with less gastrointestinal (GI) toxicity in patients with anaplastic lymphoma kinase-rearranged (ALK+) advanced/metastatic non–small cell lung cancer (NSCLC) treated with ceritinib 450-mg with food compared with 750-mg faste...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Byoung Chul, Kim, Dong-Wan, Batra, Ullas, Park, Keunchil, Kim, Sang-We, Yang, Cheng-Ta, Voon, Pei-Jye, Sriuranpong, Virote, Babu, K. Govind, Amin, Khalid, Wang, Yingbo, Sen, Paramita, Slimane, Khemaies, Geater, Sarayut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873336/
https://www.ncbi.nlm.nih.gov/pubmed/35344649
http://dx.doi.org/10.4143/crt.2021.1571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873336/
https://www.ncbi.nlm.nih.gov/pubmed/35344649
http://dx.doi.org/10.4143/crt.2021.1571

Ejemplares similares